Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data

Salvatore D'Angelo, Michele Gilio, Rita M. D'Attino, Giuliana Gualberti, Rocco Merolla, Umberto di Luzio Paparatti, Nazzarena Malavolta, Stefania Corvaglia, Antonio Marchetta, Cinzia Scambi, Nicoletta Romeo, Giorgio Pettiti, Carlo Salvarani, Maria Grazia Catanoso, Raffaele Scarpa, Luisa Costa, Roberta Ramonda, Paola Frallonardo, Maurizio Muratore, Laura QuartaGiuseppe Passiu, Gian Luca Erre, Daniele Lubrano, Enrico Tirri, Marcello Govoni, Federica Furini, Romualdo Russo, Rosario Buono, Maria Rosa Pozzi, Marta Riva, Rosa Daniela Grembiale, Caterina Bruno, Patrizia Gibertini, Antonio Marchesoni

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: To describe the baseline characteristics of the patients enrolled in the QUality of life in patients with Axial SpondyloARthritis (QUASAR) study in terms of quality of life (QoL), disease activity, therapy adherence, and work ability in a real-world setting. METHODS: QUASAR is an Italian multicentre, prospective 12-month observational study, including consecutive adult patients classified as axial spondyloarthritis (axSpA) according to the Assessment of SpondyloArthritis international Society criteria for axSpA. RESULTS: Of 512 patients enrolled in 23 rheumatology centres, 80.7% had ankylosing spondylitis (AS) and 19.3% had non-radiographic axSpA (nr-axSpA). Mean ages were 34.1±13.3 years at axSpA symptoms onset and 39.5±13.0 years at diagnosis. Of the patients, 51.4% presented with ≥1 extra articular manifestation (EAM); the most common were psoriasis (17.8%) and uveitis (16.4%). Patients with nr-axSpA and AS had similar EAM rates, disease activity, and QoL. Biologic disease-modifying anti-rheumatic drugs (bDMARDs; 83.2%) were the most commonly received medication, followed by conventional synthetic DMARDs (22.9%) and non-steroidal anti-inflammatory drugs (NSAIDs; 16.6%). At baseline, higher treatment satisfaction was reported with bDMARDs which, together with NSAIDs, were associated with the best overall scores for disease activity, function, and QoL in the overall population and AS subgroup. CONCLUSIONS: QUASAR is the first Italian prospective study that comprehensively evaluated a large axSpA patient sample in a real-world setting. This interim analysis at baseline confirmed that i) patients with AS and nr-axSpA have similar QoL and disease burden, ii) nearly all axSpA patients receive treatment, and iii) bDMARDs and NSAIDs, overall, yield better disease activity and QoL.

Original languageEnglish
Pages (from-to)748-755
Number of pages8
JournalClinical and Experimental Rheumatology
Volume37
Issue number5
Publication statusPublished - Sep 1 2019

Fingerprint

Observational Studies
Quality of Life
Ankylosing Spondylitis
Non-Steroidal Anti-Inflammatory Agents
Antirheumatic Agents
Joints
Aptitude
Uveitis
Rheumatology
Psoriasis
Anti-Inflammatory Agents
Therapeutics
Prospective Studies
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

D'Angelo, S., Gilio, M., D'Attino, R. M., Gualberti, G., Merolla, R., di Luzio Paparatti, U., ... Marchesoni, A. (2019). Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data. Clinical and Experimental Rheumatology, 37(5), 748-755.

Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR) : baseline data. / D'Angelo, Salvatore; Gilio, Michele; D'Attino, Rita M.; Gualberti, Giuliana; Merolla, Rocco; di Luzio Paparatti, Umberto; Malavolta, Nazzarena; Corvaglia, Stefania; Marchetta, Antonio; Scambi, Cinzia; Romeo, Nicoletta; Pettiti, Giorgio; Salvarani, Carlo; Catanoso, Maria Grazia; Scarpa, Raffaele; Costa, Luisa; Ramonda, Roberta; Frallonardo, Paola; Muratore, Maurizio; Quarta, Laura; Passiu, Giuseppe; Erre, Gian Luca; Lubrano, Daniele; Tirri, Enrico; Govoni, Marcello; Furini, Federica; Russo, Romualdo; Buono, Rosario; Pozzi, Maria Rosa; Riva, Marta; Grembiale, Rosa Daniela; Bruno, Caterina; Gibertini, Patrizia; Marchesoni, Antonio.

In: Clinical and Experimental Rheumatology, Vol. 37, No. 5, 01.09.2019, p. 748-755.

Research output: Contribution to journalArticle

D'Angelo, S, Gilio, M, D'Attino, RM, Gualberti, G, Merolla, R, di Luzio Paparatti, U, Malavolta, N, Corvaglia, S, Marchetta, A, Scambi, C, Romeo, N, Pettiti, G, Salvarani, C, Catanoso, MG, Scarpa, R, Costa, L, Ramonda, R, Frallonardo, P, Muratore, M, Quarta, L, Passiu, G, Erre, GL, Lubrano, D, Tirri, E, Govoni, M, Furini, F, Russo, R, Buono, R, Pozzi, MR, Riva, M, Grembiale, RD, Bruno, C, Gibertini, P & Marchesoni, A 2019, 'Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data', Clinical and Experimental Rheumatology, vol. 37, no. 5, pp. 748-755.
D'Angelo S, Gilio M, D'Attino RM, Gualberti G, Merolla R, di Luzio Paparatti U et al. Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data. Clinical and Experimental Rheumatology. 2019 Sep 1;37(5):748-755.
D'Angelo, Salvatore ; Gilio, Michele ; D'Attino, Rita M. ; Gualberti, Giuliana ; Merolla, Rocco ; di Luzio Paparatti, Umberto ; Malavolta, Nazzarena ; Corvaglia, Stefania ; Marchetta, Antonio ; Scambi, Cinzia ; Romeo, Nicoletta ; Pettiti, Giorgio ; Salvarani, Carlo ; Catanoso, Maria Grazia ; Scarpa, Raffaele ; Costa, Luisa ; Ramonda, Roberta ; Frallonardo, Paola ; Muratore, Maurizio ; Quarta, Laura ; Passiu, Giuseppe ; Erre, Gian Luca ; Lubrano, Daniele ; Tirri, Enrico ; Govoni, Marcello ; Furini, Federica ; Russo, Romualdo ; Buono, Rosario ; Pozzi, Maria Rosa ; Riva, Marta ; Grembiale, Rosa Daniela ; Bruno, Caterina ; Gibertini, Patrizia ; Marchesoni, Antonio. / Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR) : baseline data. In: Clinical and Experimental Rheumatology. 2019 ; Vol. 37, No. 5. pp. 748-755.
@article{d544509375ca44e4b8465ff07fd1f224,
title = "Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data",
abstract = "OBJECTIVES: To describe the baseline characteristics of the patients enrolled in the QUality of life in patients with Axial SpondyloARthritis (QUASAR) study in terms of quality of life (QoL), disease activity, therapy adherence, and work ability in a real-world setting. METHODS: QUASAR is an Italian multicentre, prospective 12-month observational study, including consecutive adult patients classified as axial spondyloarthritis (axSpA) according to the Assessment of SpondyloArthritis international Society criteria for axSpA. RESULTS: Of 512 patients enrolled in 23 rheumatology centres, 80.7{\%} had ankylosing spondylitis (AS) and 19.3{\%} had non-radiographic axSpA (nr-axSpA). Mean ages were 34.1±13.3 years at axSpA symptoms onset and 39.5±13.0 years at diagnosis. Of the patients, 51.4{\%} presented with ≥1 extra articular manifestation (EAM); the most common were psoriasis (17.8{\%}) and uveitis (16.4{\%}). Patients with nr-axSpA and AS had similar EAM rates, disease activity, and QoL. Biologic disease-modifying anti-rheumatic drugs (bDMARDs; 83.2{\%}) were the most commonly received medication, followed by conventional synthetic DMARDs (22.9{\%}) and non-steroidal anti-inflammatory drugs (NSAIDs; 16.6{\%}). At baseline, higher treatment satisfaction was reported with bDMARDs which, together with NSAIDs, were associated with the best overall scores for disease activity, function, and QoL in the overall population and AS subgroup. CONCLUSIONS: QUASAR is the first Italian prospective study that comprehensively evaluated a large axSpA patient sample in a real-world setting. This interim analysis at baseline confirmed that i) patients with AS and nr-axSpA have similar QoL and disease burden, ii) nearly all axSpA patients receive treatment, and iii) bDMARDs and NSAIDs, overall, yield better disease activity and QoL.",
author = "Salvatore D'Angelo and Michele Gilio and D'Attino, {Rita M.} and Giuliana Gualberti and Rocco Merolla and {di Luzio Paparatti}, Umberto and Nazzarena Malavolta and Stefania Corvaglia and Antonio Marchetta and Cinzia Scambi and Nicoletta Romeo and Giorgio Pettiti and Carlo Salvarani and Catanoso, {Maria Grazia} and Raffaele Scarpa and Luisa Costa and Roberta Ramonda and Paola Frallonardo and Maurizio Muratore and Laura Quarta and Giuseppe Passiu and Erre, {Gian Luca} and Daniele Lubrano and Enrico Tirri and Marcello Govoni and Federica Furini and Romualdo Russo and Rosario Buono and Pozzi, {Maria Rosa} and Marta Riva and Grembiale, {Rosa Daniela} and Caterina Bruno and Patrizia Gibertini and Antonio Marchesoni",
year = "2019",
month = "9",
day = "1",
language = "English",
volume = "37",
pages = "748--755",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5",

}

TY - JOUR

T1 - Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR)

T2 - baseline data

AU - D'Angelo, Salvatore

AU - Gilio, Michele

AU - D'Attino, Rita M.

AU - Gualberti, Giuliana

AU - Merolla, Rocco

AU - di Luzio Paparatti, Umberto

AU - Malavolta, Nazzarena

AU - Corvaglia, Stefania

AU - Marchetta, Antonio

AU - Scambi, Cinzia

AU - Romeo, Nicoletta

AU - Pettiti, Giorgio

AU - Salvarani, Carlo

AU - Catanoso, Maria Grazia

AU - Scarpa, Raffaele

AU - Costa, Luisa

AU - Ramonda, Roberta

AU - Frallonardo, Paola

AU - Muratore, Maurizio

AU - Quarta, Laura

AU - Passiu, Giuseppe

AU - Erre, Gian Luca

AU - Lubrano, Daniele

AU - Tirri, Enrico

AU - Govoni, Marcello

AU - Furini, Federica

AU - Russo, Romualdo

AU - Buono, Rosario

AU - Pozzi, Maria Rosa

AU - Riva, Marta

AU - Grembiale, Rosa Daniela

AU - Bruno, Caterina

AU - Gibertini, Patrizia

AU - Marchesoni, Antonio

PY - 2019/9/1

Y1 - 2019/9/1

N2 - OBJECTIVES: To describe the baseline characteristics of the patients enrolled in the QUality of life in patients with Axial SpondyloARthritis (QUASAR) study in terms of quality of life (QoL), disease activity, therapy adherence, and work ability in a real-world setting. METHODS: QUASAR is an Italian multicentre, prospective 12-month observational study, including consecutive adult patients classified as axial spondyloarthritis (axSpA) according to the Assessment of SpondyloArthritis international Society criteria for axSpA. RESULTS: Of 512 patients enrolled in 23 rheumatology centres, 80.7% had ankylosing spondylitis (AS) and 19.3% had non-radiographic axSpA (nr-axSpA). Mean ages were 34.1±13.3 years at axSpA symptoms onset and 39.5±13.0 years at diagnosis. Of the patients, 51.4% presented with ≥1 extra articular manifestation (EAM); the most common were psoriasis (17.8%) and uveitis (16.4%). Patients with nr-axSpA and AS had similar EAM rates, disease activity, and QoL. Biologic disease-modifying anti-rheumatic drugs (bDMARDs; 83.2%) were the most commonly received medication, followed by conventional synthetic DMARDs (22.9%) and non-steroidal anti-inflammatory drugs (NSAIDs; 16.6%). At baseline, higher treatment satisfaction was reported with bDMARDs which, together with NSAIDs, were associated with the best overall scores for disease activity, function, and QoL in the overall population and AS subgroup. CONCLUSIONS: QUASAR is the first Italian prospective study that comprehensively evaluated a large axSpA patient sample in a real-world setting. This interim analysis at baseline confirmed that i) patients with AS and nr-axSpA have similar QoL and disease burden, ii) nearly all axSpA patients receive treatment, and iii) bDMARDs and NSAIDs, overall, yield better disease activity and QoL.

AB - OBJECTIVES: To describe the baseline characteristics of the patients enrolled in the QUality of life in patients with Axial SpondyloARthritis (QUASAR) study in terms of quality of life (QoL), disease activity, therapy adherence, and work ability in a real-world setting. METHODS: QUASAR is an Italian multicentre, prospective 12-month observational study, including consecutive adult patients classified as axial spondyloarthritis (axSpA) according to the Assessment of SpondyloArthritis international Society criteria for axSpA. RESULTS: Of 512 patients enrolled in 23 rheumatology centres, 80.7% had ankylosing spondylitis (AS) and 19.3% had non-radiographic axSpA (nr-axSpA). Mean ages were 34.1±13.3 years at axSpA symptoms onset and 39.5±13.0 years at diagnosis. Of the patients, 51.4% presented with ≥1 extra articular manifestation (EAM); the most common were psoriasis (17.8%) and uveitis (16.4%). Patients with nr-axSpA and AS had similar EAM rates, disease activity, and QoL. Biologic disease-modifying anti-rheumatic drugs (bDMARDs; 83.2%) were the most commonly received medication, followed by conventional synthetic DMARDs (22.9%) and non-steroidal anti-inflammatory drugs (NSAIDs; 16.6%). At baseline, higher treatment satisfaction was reported with bDMARDs which, together with NSAIDs, were associated with the best overall scores for disease activity, function, and QoL in the overall population and AS subgroup. CONCLUSIONS: QUASAR is the first Italian prospective study that comprehensively evaluated a large axSpA patient sample in a real-world setting. This interim analysis at baseline confirmed that i) patients with AS and nr-axSpA have similar QoL and disease burden, ii) nearly all axSpA patients receive treatment, and iii) bDMARDs and NSAIDs, overall, yield better disease activity and QoL.

UR - http://www.scopus.com/inward/record.url?scp=85072508576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072508576&partnerID=8YFLogxK

M3 - Article

C2 - 30943145

AN - SCOPUS:85072508576

VL - 37

SP - 748

EP - 755

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5

ER -